chr16-2088506-A-G
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP6
The NM_000548.5(TSC2):āc.5320A>Gā(p.Ser1774Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,612,704 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S1774I) has been classified as Uncertain significance.
Frequency
Consequence
NM_000548.5 missense
Scores
Clinical Significance
Conservation
Publications
- autosomal dominant polycystic kidney diseaseInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- polycystic kidney disease 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- autosomal recessive polycystic kidney diseaseInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- Caroli diseaseInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152150Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.00000400 AC: 1AN: 250054 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460554Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 726572 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152150Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74334 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not specified Uncertain:1
DNA sequence analysis of the TSC2 gene demonstrated a sequence change, c.5320A>G, in exon 42 that results in an amino acid change, p.Ser1774Gly. This sequence change does not appear to have been previously described in individuals with TSC2-related disorders. This sequence change has been described in the gnomAD database in two individuals which corresponds to a population frequency of 0.00071% (dbSNP rs368083145). The p.Ser1774Gly change affects a poorly conserved amino acid residue located in a domain of the TSC2 protein that is not known to be functional. The p.Ser1774Gly substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Ser1774Gly change remains unknown at this time.
Tuberous sclerosis syndrome Uncertain:1
This missense variant replaces serine with glycine at codon 1774 of the TSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with TSC2-related disorders in the literature. This variant has been identified in 2/281432 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Hereditary cancer-predisposing syndrome Uncertain:1
The p.S1774G variant (also known as c.5320A>G), located in coding exon 41 of the TSC2 gene, results from an A to G substitution at nucleotide position 5320. The serine at codon 1774 is replaced by glycine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Tuberous sclerosis 2 Benign:1
not provided Benign:1
TSC2: BP4
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at